JP2017515854A5 - - Google Patents

Download PDF

Info

Publication number
JP2017515854A5
JP2017515854A5 JP2016567605A JP2016567605A JP2017515854A5 JP 2017515854 A5 JP2017515854 A5 JP 2017515854A5 JP 2016567605 A JP2016567605 A JP 2016567605A JP 2016567605 A JP2016567605 A JP 2016567605A JP 2017515854 A5 JP2017515854 A5 JP 2017515854A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
subject
liver disease
liver
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016567605A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017515854A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/030101 external-priority patent/WO2015175381A1/en
Publication of JP2017515854A publication Critical patent/JP2017515854A/ja
Publication of JP2017515854A5 publication Critical patent/JP2017515854A5/ja
Pending legal-status Critical Current

Links

JP2016567605A 2014-05-12 2015-05-11 カスパーゼ阻害剤による慢性肝疾患の合併症の治療 Pending JP2017515854A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461992169P 2014-05-12 2014-05-12
US61/992,169 2014-05-12
PCT/US2015/030101 WO2015175381A1 (en) 2014-05-12 2015-05-11 Treatment of the complications of chronic liver disease with caspase inhibitors

Publications (2)

Publication Number Publication Date
JP2017515854A JP2017515854A (ja) 2017-06-15
JP2017515854A5 true JP2017515854A5 (OSRAM) 2018-06-21

Family

ID=53276268

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016567605A Pending JP2017515854A (ja) 2014-05-12 2015-05-11 カスパーゼ阻害剤による慢性肝疾患の合併症の治療

Country Status (15)

Country Link
US (2) US20170100448A1 (OSRAM)
EP (2) EP3444011A1 (OSRAM)
JP (1) JP2017515854A (OSRAM)
KR (1) KR20170015312A (OSRAM)
CN (1) CN106470679A (OSRAM)
AU (1) AU2015259471A1 (OSRAM)
BR (1) BR112016026560A2 (OSRAM)
CA (1) CA2948540A1 (OSRAM)
ES (1) ES2751652T3 (OSRAM)
IL (1) IL248882A0 (OSRAM)
MX (1) MX2016014731A (OSRAM)
RU (1) RU2016148364A (OSRAM)
SG (1) SG11201609256SA (OSRAM)
WO (1) WO2015175381A1 (OSRAM)
ZA (1) ZA201607740B (OSRAM)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017079566A1 (en) * 2015-11-05 2017-05-11 Conatus Pharmaceuticals, Inc. Caspase inhibitors for use in the treatment of liver cancer
JP2019500397A (ja) * 2015-12-31 2019-01-10 クオナトウス ファーマシューティカルズ,インコーポレイテッド カスパーゼ阻害剤を肝疾患の治療に使用する方法
FR3050112B1 (fr) 2016-04-15 2020-09-04 Soc Civ Immobiliere Gecinq Utilisation de l'acide fenofibrique dans le traitement des maladies hepatiques
EP3456711A4 (en) * 2016-05-11 2019-10-16 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. CASPASE INHIBITOR AND PHARMACEUTICAL COMPOSITION, USE AND THERAPEUTIC METHOD THEREFOR
US20190351003A1 (en) * 2017-02-07 2019-11-21 The Regents Of The University Of California Methods for inhibiting nonalcoholic steatohepatitis, nonalcoholic fatty liver disease, and/or de novo lipogenesis
KR20200052331A (ko) * 2017-09-13 2020-05-14 노파르티스 아게 알코올성 간염의 치료를 위한 il-1b 결합 항체의 용도
CN109748843B (zh) * 2017-11-06 2022-11-11 正大天晴药业集团股份有限公司 Caspase抑制剂及其药物组合物、用途和治疗方法
CA3105352A1 (en) 2018-06-29 2020-01-02 Histogen, Inc. (s)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases
CA3102755A1 (en) * 2018-06-29 2020-01-02 The Doshisha Formulation containing emricasan
ES2988904T3 (es) * 2019-03-07 2024-11-22 Nobo Medicine Inc Inhibidores de caspasa y métodos de utilización de los mismos
KR102442103B1 (ko) * 2019-04-30 2022-09-08 주식회사 엘지화학 캐스파제 저해제의 프로드럭
US20230338459A1 (en) * 2020-04-14 2023-10-26 Amerimmune, Llc Treatment for Diseases Caused by RNA Viruses
MX2022013549A (es) 2020-05-01 2023-01-16 Medstar Health Inc Metodos para tratar la covid-19.
WO2022271877A2 (en) * 2021-06-22 2022-12-29 Amerimmune, Llc. Treatment for diseases caused by rna viruses

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
GB1429184A (en) 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
US4044126A (en) 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
KR890002631B1 (ko) 1984-10-04 1989-07-21 몬산토 캄파니 생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
US5523092A (en) 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US5985307A (en) 1993-04-14 1999-11-16 Emory University Device and method for non-occlusive localized drug delivery
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5759542A (en) 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US6316652B1 (en) 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
DE69632684T2 (de) 1995-06-27 2005-06-09 Takeda Pharmaceutical Co. Ltd. Verfahren zur herstellung von zubereitungen mit verzögerter freisetzung
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US6039975A (en) 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
TW345603B (en) 1996-05-29 1998-11-21 Gmundner Fertigteile Gmbh A noise control device for tracks
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
US6139865A (en) 1996-10-01 2000-10-31 Eurand America, Inc. Taste-masked microcapsule compositions and methods of manufacture
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
EP0839525B1 (en) 1996-10-31 2004-08-04 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6131570A (en) 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
DK0946169T3 (da) 1996-12-20 2003-04-22 Takeda Chemical Industries Ltd Fremgangsmåde til fremstilling af et præparat med vedvarende frigivelse
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
US7053056B2 (en) 1998-07-02 2006-05-30 Idun Pharmaceuticals, Inc. C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US6544951B2 (en) 1998-07-02 2003-04-08 Idun Pharmaceuticals, Inc. C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US6197750B1 (en) 1998-07-02 2001-03-06 Idun Pharmaceuticals, Inc. C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US6559304B1 (en) 1998-08-19 2003-05-06 Vertex Pharmaceuticals Incorporated Method for synthesizing caspase inhibitors
US6201118B1 (en) 1998-08-19 2001-03-13 Vertex Pharmaceuticals Inc. Process for forming an N-acylated, N,N-containing bicyclic ring from piperazic acid or an ester thereof especially useful as an intermediate in the manufacture of a caspase inhibitor
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
DE60010675T2 (de) 1999-08-06 2005-06-16 Vertex Pharmaceuticals Inc., Cambridge Caspase inhibitoren und deren verwendung
US6790989B2 (en) 2000-01-13 2004-09-14 Idun Pharmaceuticals, Inc. Inhibitors of the ICE/ced-3 family of cysteine proteases
MXPA02009633A (es) 2000-03-29 2003-03-10 Vertex Pharma Inhibidores de carbamato caspasa y usos de los mismos.
MXPA02000823A (es) 2000-05-23 2002-07-30 Vertex Pharma Inhibidores de caspasa y uso de los mismos.
WO2001094351A1 (en) 2000-06-07 2001-12-13 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
WO2002022611A2 (en) 2000-09-13 2002-03-21 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
US6665495B1 (en) 2000-10-27 2003-12-16 Yotta Networks, Inc. Non-blocking, scalable optical router architecture and method for routing optical traffic
MXPA03009647A (es) 2001-04-19 2004-01-29 Vertex Pharma Heterociclildicarbamidas como inhibidores de caspasa.
WO2002094263A2 (en) 2001-05-23 2002-11-28 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
WO2003068242A1 (en) 2002-02-11 2003-08-21 Vertex Pharmaceuticals Incorporated Phospholipids as caspase inhibitor prodrugs
US7553852B2 (en) 2002-06-28 2009-06-30 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
AU2003303345A1 (en) 2002-12-20 2004-07-22 Vertex Pharmaceuticals, Inc. 4-oxo-3-(1-oxo-1h-isoquinolin-2-ylacetylamino)-pentanoic acid ester and amide derivatives and their use as caspase inhibitors
PE20050159A1 (es) 2003-05-27 2005-04-19 Vertex Pharma Derivados de acido 3-[2-(3-amino-2-oxo-2h-piridin-1-il)-acetilamino]-4-oxo-pentanoico como inhibidores de caspasa
KR100594544B1 (ko) 2003-08-27 2006-06-30 주식회사 엘지생명과학 이소옥사졸린 구조를 갖는 캐스파제 저해제
AR047981A1 (es) 2004-02-27 2006-03-15 Vertex Pharma Inhibidores de caspasa y sus usos correspondientes
JP2005319019A (ja) 2004-05-07 2005-11-17 Bridgestone Sports Co Ltd ゴルフクラブヘッド
US20100190688A1 (en) 2004-07-12 2010-07-29 Bin Chao Tetrapeptide analogs
PT2091910E (pt) 2006-12-06 2014-11-18 Conatus Pharmaceuticals Inc Formas cristalinas do ácido (3s)-3-[n-(n¿-(2-tercbutilfenil) oxamil)alaninil]amino-5-(2¿,3¿,5¿,6¿- tetrafluorofenoxi)-4-oxopentanóico
WO2008106167A1 (en) * 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
RU2496514C2 (ru) * 2008-06-05 2013-10-27 Займоджинетикс, Инк. Применение пэгилированных интерферонов типа iii для лечения гепатита с
WO2012103520A1 (en) * 2011-01-28 2012-08-02 Board Of Regents Of The University Of Nebraska Methods and compositions for modulating cyclophilin d
CA2842707A1 (en) 2011-08-04 2013-02-07 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of pancreatitis
WO2013063526A1 (en) 2011-10-28 2013-05-02 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease
EA030839B1 (ru) 2011-10-28 2018-10-31 ЛУМЕНА ФАРМАСЬЮТИКАЛС ЭлЭлСи Ингибиторы рециклинга желчных кислот при лечении холестатических заболеваний печени у детей

Similar Documents

Publication Publication Date Title
JP2017515854A5 (OSRAM)
JP2018507914A5 (OSRAM)
NZ625592A (en) Compositions and methods for the treatment of hepatic diseases and disorders
JP2018030855A5 (OSRAM)
SG10201407013QA (en) Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
HRP20240097T1 (hr) Supstituirani diaminokarboksamid i diaminokarbonitril pirimidini, njihovi pripravci i postupci liječenja s njima
JP2020505423A5 (OSRAM)
NZ586751A (en) Use of CDDO methyl ester (methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28-oate) for the treatment of renal diseases and for improving kigney function
EA201792541A3 (ru) Ингибиторы рециркуляции желчных кислот для лечения гиперхолемии и холестатического заболевания печени
JP2013509429A5 (OSRAM)
JP2017515901A5 (OSRAM)
JP2014507446A5 (OSRAM)
EA201200096A1 (ru) Фармацевтическая композиция ингибитора протеазы вируса гепатита c
JP2016511753A5 (OSRAM)
JP2011527299A5 (OSRAM)
JP2016534063A5 (OSRAM)
MX2017012319A (es) Metodos para tratar enfermedad hepática utilizando derivados de acido indano acético.
RU2015136849A (ru) Композиции, содержащие 15-он эпк, и способы их применения
JP2016510326A5 (OSRAM)
RU2015114543A (ru) Способы лечения гепатита с
JP2010520200A5 (OSRAM)
JP2017508817A5 (OSRAM)
JP2013508282A5 (OSRAM)
JP2016512817A5 (OSRAM)
JP2017523790A5 (OSRAM)